ARTICLE | Clinical News
TLC C-53 liposomal prostaglandin E1: Began Phase III trial in 350 patients. The primary end point is time to removal from mechanical ventilation.
October 2, 1995 7:00 AM UTC
The Liposome Co. Inc. (LIPO), Princeton, N.J. Product: TLC C-53 liposomal prostaglandin E1 Indication: Acute respiratory distress syndrome (ARDS) Status: Began Phase III trial in 350 patients. The pri...